Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 in Combination With Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers (10041848, 10008224, 10008238, 10046888, 10014735)

Next Previous
X
Search
Trial Profile

A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 in Combination With Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers (10041848, 10008224, 10008238, 10046888, 10014735)

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adavosertib (Primary) ; Cisplatin
  • Indications Adenocarcinoma; Carcinoma; Cervical cancer; Endometrial cancer; Uterine cancer; Vulvovaginal cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 25 Jan 2024 Status changed from active, no longer recruiting to discontinued due to insufficient accrual rate.
    • 23 Sep 2023 Planned End Date changed from 28 Nov 2023 to 21 Sep 2024.
    • 09 Jun 2023 Interventional study model has been changed to single group assignment and sequential has been removed, number of treatment arms has been changed to 1 from 2.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top